Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ulka Vaishampayan

Showing results (61-70 of 176) with videos related to

Pageof 18
Sort By:
Journal for Immunotherapy of Cancer|March 15, 2019
Perception of cure among patients with metastatic genitourinary cancer initiating immunotherapyCristiane Decat Bergerot, Paulo Gustavo Bergerot, Errol J Philip, et al.
Clinical Genitourinary Cancer|March 15, 2018
Phase I Trial of the Combination of Docetaxel, Prednisone, and Pasireotide in Metastatic Castrate-Resistant Prostate CancerManish K Thakur, Lance Heilbrun, Kimberlee Dobson, et al.
Cancer Immunology, Immunotherapy : CII|June 10, 2019
An HER2 DNA vaccine with evolution-selected amino acid substitutions reveals a fundamental principle for cancer vaccine formulation in HER2 transgenic miceRichard F Jones, Joyce D Reyes, Heather M Gibson, et al.
Urology|September 17, 2015
Phase II Trial of Carboplatin, Everolimus, and Prednisone in Metastatic Castration-resistant Prostate Cancer Pretreated With Docetaxel Chemotherapy: A Prostate Cancer Clinical Trial Consortium StudyUlka Vaishampayan, Daniel Shevrin, Mark Stein, et al.
Experimental Hematology & Oncology|October 14, 2017
Pharmacokinetics of carfilzomib in patients with advanced malignancies and varying degrees of hepatic impairment: an open-label, single-arm, phase 1 studyJennifer Brown, Ruth Plummer, Todd M Bauer, et al.
Biomaterials|September 5, 2018
Tumor hypoxia directed multimodal nanotherapy for overcoming drug resistance in renal cell carcinoma and reprogramming macrophagesHashem O Alsaab, Samaresh Sau, Rami M Alzhrani, et al.
International Journal of Radiation Oncology, Biology, Physics|May 18, 2004
Intensity-modulated radiotherapy (IMRT) and concurrent capecitabine for pancreatic cancerEdgar Ben-Josef, Anthony F Shields, Ulka Vaishampayan, et al.
Investigational New Drugs|August 6, 2022
Phase 1 study to evaluate the effects of rifampin on pharmacokinetics of pevonedistat, a NEDD8-activating enzyme inhibitor in patients with advanced solid tumorsXiaofei Zhou, Ulka Vaishampayan, Devalingam Mahalingam, et al.
The Journal of Urology|January 22, 2008
Neoadjuvant docetaxel and capecitabine in patients with high risk prostate cancerJudah Friedman, Rodney L Dunn, David Wood, et al.
Cancer Immunology Research|February 26, 2015
Induction of HER2 Immunity in Outbred Domestic Cats by DNA ElectrovaccinationHeather M Gibson, Jesse J Veenstra, Richard Jones, et al.
Pageof 18

Showing results (61-70 of 176) with videos related to

Sort By:
Pageof 18
Journal for Immunotherapy of Cancer|March 15, 2019
Perception of cure among patients with metastatic genitourinary cancer initiating immunotherapyCristiane Decat Bergerot, Paulo Gustavo Bergerot, Errol J Philip, et al.
Clinical Genitourinary Cancer|March 15, 2018
Phase I Trial of the Combination of Docetaxel, Prednisone, and Pasireotide in Metastatic Castrate-Resistant Prostate CancerManish K Thakur, Lance Heilbrun, Kimberlee Dobson, et al.
Cancer Immunology, Immunotherapy : CII|June 10, 2019
An HER2 DNA vaccine with evolution-selected amino acid substitutions reveals a fundamental principle for cancer vaccine formulation in HER2 transgenic miceRichard F Jones, Joyce D Reyes, Heather M Gibson, et al.
Urology|September 17, 2015
Phase II Trial of Carboplatin, Everolimus, and Prednisone in Metastatic Castration-resistant Prostate Cancer Pretreated With Docetaxel Chemotherapy: A Prostate Cancer Clinical Trial Consortium StudyUlka Vaishampayan, Daniel Shevrin, Mark Stein, et al.
Experimental Hematology & Oncology|October 14, 2017
Pharmacokinetics of carfilzomib in patients with advanced malignancies and varying degrees of hepatic impairment: an open-label, single-arm, phase 1 studyJennifer Brown, Ruth Plummer, Todd M Bauer, et al.
Biomaterials|September 5, 2018
Tumor hypoxia directed multimodal nanotherapy for overcoming drug resistance in renal cell carcinoma and reprogramming macrophagesHashem O Alsaab, Samaresh Sau, Rami M Alzhrani, et al.
International Journal of Radiation Oncology, Biology, Physics|May 18, 2004
Intensity-modulated radiotherapy (IMRT) and concurrent capecitabine for pancreatic cancerEdgar Ben-Josef, Anthony F Shields, Ulka Vaishampayan, et al.
Investigational New Drugs|August 6, 2022
Phase 1 study to evaluate the effects of rifampin on pharmacokinetics of pevonedistat, a NEDD8-activating enzyme inhibitor in patients with advanced solid tumorsXiaofei Zhou, Ulka Vaishampayan, Devalingam Mahalingam, et al.
The Journal of Urology|January 22, 2008
Neoadjuvant docetaxel and capecitabine in patients with high risk prostate cancerJudah Friedman, Rodney L Dunn, David Wood, et al.
Cancer Immunology Research|February 26, 2015
Induction of HER2 Immunity in Outbred Domestic Cats by DNA ElectrovaccinationHeather M Gibson, Jesse J Veenstra, Richard Jones, et al.
Pageof 18